Drug Dictionary Pdf Free Download
Louann Tandy
Multum leaflets provide basic consumer drug information, such as drug descriptions and interactions, details of possible side effects and the effects of missed doses and overdosing, as well as instructions for use. The leaflets are available in English and Spanish.
Micromedex Advanced Consumer Information provides comprehensive consumer information pertaining to a wide variety of drugs, such as a list of commonly used brand names, drug descriptions, warnings and precautions, and detailed information on the proper use of each drug.
AHFS DI from the American Society of Health-System Pharmacists (ASHP) is the most comprehensive source of unbiased and authoritative drug information available to health professionals today. A wholly independent staff of drug information pharmacists and other professional editorial and analytical staff thoroughly research AHFS DI content. Authors incorporate clinical research findings, therapeutic guidelines, and Food and Drug Administration (FDA) approved labeling to ensure that monographs include an evidence-based foundation for safe and effective drug therapy.
The Natural Product Information (Consumer) database is a comprehensive source of information on traditional and/or conventional uses of natural products. A basic overview of each product is provided (including dosages, possible drug interactions, side effects and contraindications) along with safety and/or efficacy ratings.
The natural product information (professional) database is a comprehensive source of information on traditional and/or conventional uses of natural products. A basic overview of each product is provided (including dosages, possible drug interactions, side effects and contraindications) along with safety and/or efficacy ratings.
NCI Dictionary of Cancer Terms
A dictionary of cancer and biomedical terms defined in non-technical language. Terms and definitions are reviewed by a multidisciplinary panel of reviewers and new terms are added each month.
NCI Dictionary of Genetics Terms
A dictionary of genetics terms written for healthcare professionals. This resource was developed to support the comprehensive, evidence-based, peer-reviewed PDQ cancer genetics information summaries.
NCI Drug Dictionary
The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.
It includes codes for prescription and non-prescription drugs, dietary supplements, and other herbal and natural products. These codes are linked to their active ingredients, allowing investigators to identify groups of exposures according to component (e.g., all acetaminophen exposures regardless of brand, single vs. multiple entity), according to class (e.g., CNS/Analgesic-Antipyretic), or according to specific product (e.g., generic acetaminophen).
Updated monthly, the Slone Drug Dictionary currently contains over 17,000 entries for single entity medicinal agents and over 12,000 multi-component products. The dictionary has the capacity to classify new products while retaining historical information on formulation changes. It also contains entries which may not appear in many commercial databases, including international drug names, compounded medications, dietary supplements, and investigational drugs.
A chemical substance such as a narcotic or a hallucinogen that affects the central nervous system and is used recreationally for perceived desirable effects on personality, perception, or behavior. Many recreational drugs are used illicitly and can be addictive.
Objective: Drugs have tremendous potential to cure and relieve disease, but the risk of unintended effects is always present. Healthcare providers increasingly record data in electronic patient records (EPRs), in which we aim to identify possible adverse events (AEs) and, specifically, possible adverse drug events (ADEs).
Materials and methods: Based on the undesirable effects section from the summary of product characteristics (SPC) of 7446 drugs, we have built a Danish ADE dictionary. Starting from this dictionary we have developed a pipeline for identifying possible ADEs in unstructured clinical narrative text. We use a named entity recognition (NER) tagger to identify dictionary matches in the text and post-coordination rules to construct ADE compound terms. Finally, we apply post-processing rules and filters to handle, for example, negations and sentences about subjects other than the patient. Moreover, this method allows synonyms to be identified and anatomical location descriptions can be merged to allow appropriate grouping of effects in the same location.
Discussion: The presented dictionary-building method could be used to construct other ADE dictionaries. The complication of compound words in Germanic languages was addressed. Additionally, the synonym and anatomical location collapse improve the method.
ARCOS is an automated, comprehensive drug reporting system which monitors the flow of DEA controlled substances from their point of manufacture through commercial distribution channels to point of sale or distribution at the dispensing/retail level - hospitals, retail pharmacies, practitioners, mid-level practitioners, and teaching institutions. Included in the list of controlled substance transactions tracked by ARCOS are the following: All Schedules I and II materials (manufacturers and distributors); Schedule III narcotic and gamma-hydroxybutyric acid (GHB) materials (manufacturers and distributors); and selected Schedule III and IV psychotropic drugs (manufacturers only).
ARCOS accumulates these transactions which are then summarized into reports which give investigators in Federal and state government agencies information which can then be used to identify the diversion of controlled substances into illicit channels of distribution. The information on drug distribution is used throughout the United States (U.S.). by U.S. Attorneys and DEA investigators to strengthen criminal cases in the courts.
The European Medicines Agency (EMA) offers training on how to submit and retrieve medicinal product data using the extended EudraVigilance medicinal product dictionary (XEVMPD), also known as Article 57 database. This is aimed at ensuring the quality of data in the XEVMPD on authorised or investigational medicinal products. At least one user from each marketing authorisation holder or sponsor of clinical trials should receive training.
The NDC Directory contains information on active and certified finished and unfinished drugs submitted to FDA in structured product labeling (SPL) electronic listing files by labelers. A labeler may be a manufacturer, including a repackager or relabeler, or the entity named on the product label.
Drug establishments producing active pharmaceutical ingredients are required to provide FDA with a current list of all drugs manufactured, prepared, propagated, compounded or processed in commercial distribution in the U.S. at their facilities.
The NDC unfinished drugs database contains product listing data submitted for all unfinished drugs, including active pharmaceutical ingredients, drugs for further processing and bulk drug substances for compounding.
Outsourcing facilities are required to provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year. The NDC Directory draws data from these product reports.
For finished drugs and unfinished drug products: Submit a new or updated product listing through SPL to add, correct or update product listing information in the NDC Directory. FDA does not submit or alter registration or listing data. Accuracy of the listing data is the responsibility of the company submitting the information to FDA. The agency monitors data accuracy and integrity through its compliance program. See the DRLS instructions for more information.
For compounded drugs: Outsourcing facilities submit product reports for compounded drugs twice a year and may update this data at any time. Outsourcing facilities should submit new or updated product reporting information through SPL to add, correct or update product reporting information that displays in the NDC Directory (see FDA guidance document on product reporting for outsourcing facilities).
This dictionary covers all the major areas of sports science and medicine including: anatomy, biomechanics, exercise physiology, nutrition, sports psychology, sports sociology, sports injuries, and training principles. It was compiled with the help of a team of eminent contributors and advisers; the third edition has been updated to incorporate recent advances, for example in the areas of gene technology and drug and doping regulations.
It is used by pharmaceutical companies, clinical trial organizations and drug regulatory authorities for identifying drug names in spontaneous ADR reporting (and pharmacovigilance) and in clinical trials.[2] Created in 1968 and regularly updated, since 2005 there have been major developments in the form of a WHO Drug Dictionary Enhanced (with considerably more fields and data entries) and a WHO Herbal Dictionary, which covers traditional and herbal medicines. Since 2016 all of the WHODrug products have been available in a single subscription service called WHODrug Global.[3]
OrganizationWHODrug drug code consist of 11 characters (alphanumeric code). It has 3 parts: Drug Record Number(Drug Rec No), Sequence number 1(Seq1) and Sequence number 2 (Seq2). Drug Rec No consists of 6 characters. It uniquely identifies active moieties, regardless of salt form or plant part and extract. Seq1 is used to uniquely identify different variations (e.g. salts and esters), plant parts and extraction methods, thereby defining active substances or a combination of active substances. WHODrug records sharing the same Drug Rec No and Seq1 contain the same variation/plant part/extract variation of the same active moiety. For single-ingredient records, Seq1=01 identifies a specific active moiety. If Seq1 is higher than 01 it refers to variations of that active moiety. For multi-ingredient records, Seq1=01 identifies a combination of active moieties. If Seq1 is higher than 01 it refers to variations of one or more of the active moieties in the combination. Finally, Seq2 uniquely identifies the name of the record in WHODrug.
f448fe82f3